Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | MicrobiomeTrials← Back to trialsNCT07562152
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-06Est. Completion: 2028-06
Enrollment target: 510 participants Locations- City of Hope, Phoenix, Arizona, United States
- City of Hope, Duarte, California, United States
- Piedmont Healthcare, Atlanta, Georgia, United States
- City of Hope, Chicago, Illinois, United States
- Missouri Cancer Associates, Columbia, Missouri, United States
- Comprehensive Cancer Centers, Las Vegas, Nevada, United States
- Regional Cancer Care, Belleville, New Jersey, United States
- NYU Langone Health, New York, New York, United States
- Taylor Cancer Research Center, Maumee, Ohio, United States
- Sarah Cannon Research Institute, Nashville, Tennessee, United States
- Texas Oncology Gulf Coast, Webster, Texas, United States
- Blue Ridge Cancer Care, Blacksburg, Virginia, United States
- Calvary Mater Newcastle, Waratah, New South Wales, Australia
Other microbiome trials you might be interested in
Advanced CancerPancreatic Cancer
This is a prospective, single-arm, pilot feasibility clinical trial designed to evaluate the feasibility and safety of a…
Toronto, CanadaEst. completion Jun 1, 2027
Pancreatic Malignant Neoplasm Primary
This study will be a retrospective chart review of patients who have been diagnosed with benign or malignant pancreatic …
Richardson, United StatesCompleted Feb 27, 2021
Immuneering Study Team
Recruiting
Pancreatic Ductal Adenocarcinoma
Phase II, open-label, single-arm study of CD40/Dectin-1 immunotherapy as maintenance treatment in patients with unresect…
Philadelphia, United StatesEst. completion Oct 2027